Financings in Brief: Med-Design Corporation
This article was originally published in The Gray Sheet
Executive SummaryMed-Design Corporation: Files registration statement with the Securities and Exchange Commission for an initial public offering of 1.5 mil. shares of common stock, expected to be sold for between $6.50 and $7 per share. Based in Philadelphia, Med-Design is developing safety devices intended to lower the incidence of accidental needlesticks. The firm's first three products are a safety syringe, a safety phlebotomy set, and a safety catheter. Each product features a retractable needle that is rendered risk-free once therapy is delivered. The 11-employee company anticipates that FDA will determine all three products to be Class II devices and that 510(k)s for all three will be filed by the end of 1995.
You may also be interested in...
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.